Regencell Bioscience Holdings Limited Stock Prediction and Forecast [RGC]

AI-generated source summary

The analysis focuses on RegentCell Bioscience Holdings (RGC). Since September 4th, the system has classified it as a sell candidate with a score of -2.578, despite a 3.66% gain and a 0.73% average daily gain over the past 5 days. The short-term trend is declining, suggesting a selling opportunity. A break above the upper trend line at $25.78 would indicate a slower decline and a potential trend shift. The three-month trend projects a change of -87.39%, with a potential range from -100% to -75.58%. The 12-month analysis forecasts a change between 20.76% and 8261.38%. The stock experiences resistance around $13.50 and support around $13.30. Volume is decreasing with the price, which is a positive sign because the volume usually follows the price. The stock is assigned a 'strong sell' rating by analysts, who have not recently engaged in insider trading.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   11 Sept 2025, 03:17 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   18 Jul 2026, 12:39 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   18 Jul 2026, 12:39 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   18 Jul 2026, 12:39 UTC

   All evaluable predictions in this case reached terminal outcomes.